PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 153 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 1.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $98,000 | -16.2% | 15,642 | +7.7% | 0.00% | 0.0% |
| Q2 2018 | $117,000 | -32.8% | 14,520 | -43.3% | 0.00% | 0.0% |
| Q1 2018 | $174,000 | +163.6% | 25,630 | +130.7% | 0.00% | +100.0% |
| Q4 2017 | $66,000 | +8.2% | 11,110 | +34.0% | 0.00% | 0.0% |
| Q3 2017 | $61,000 | +41.9% | 8,294 | +31.8% | 0.00% | 0.0% |
| Q2 2017 | $43,000 | +53.6% | 6,292 | +115.0% | 0.00% | 0.0% |
| Q1 2017 | $28,000 | – | 2,926 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Phocas Financial Corp. | 1,033,328 | $6,376,000 | 0.68% |
| ARDSLEY ADVISORY PARTNERS LP | 650,000 | $4,011,000 | 0.63% |
| Worth Venture Partners, LLC | 138,357 | $853,000 | 0.47% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,242,503 | $13,836,000 | 0.46% |
| HIGHLAND CAPITAL MANAGEMENT LP | 716,880 | $4,423,000 | 0.26% |
| FARALLON CAPITAL MANAGEMENT LLC | 5,543,386 | $34,203,000 | 0.22% |
| Point72 Asset Management, L.P. | 5,858,749 | $36,148,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,298,723 | $8,013,000 | 0.19% |
| Fosun International Ltd | 472,580 | $2,750,000 | 0.18% |
| J. Goldman & Co LP | 400,000 | $2,468,000 | 0.17% |